Leap Therapeutics Liabilities 2024

Leap Therapeutics Aktienanalyse

What does Leap Therapeutics do?

Leap Therapeutics Inc is a biotechnology company based in Cambridge, Massachusetts. The company was founded in 2011 as HealthCare Pharmaceuticals Inc. and specializes in the development of new cancer therapies. The company's history began with the discovery of LIM kinase (LIMK) as a new target molecule for cancer therapies. This protein plays a role in the regulation of the cytoskeleton, which is important for cell shape and movement. Inhibiting LIMK could therefore inhibit the growth and spread of cancer cells. Leap Therapeutics has subsequently focused on the development of antibody therapies targeted against various types of cancer. The company employs a combination therapy approach, consisting of multiple drugs tailored to the specific characteristics of the tumor. The goal is to increase treatment efficacy while reducing potential side effects. Leap Therapeutics currently has several clinical trials underway, focusing on different types of cancer such as breast, lung, and colorectal cancer. A key focus is on developing therapies for patients with advanced or metastatic cancer for whom conventional treatment methods are no longer sufficient. One example of a Leap Therapeutics product is the antibody DKN-01, which targets the growth factors DKK1 and DKK2. These factors play a role in the regulation of tumor growth and metastasis and are elevated in many types of cancer. Clinical studies have shown that DKN-01 in combination with the chemotherapy drug paclitaxel has a higher response rate in patients with lung cancer compared to chemotherapy alone. Another Leap Therapeutics product is the antibody TRX518, which specifically targets the immune receptor OX40. OX40 plays a role in the activation of T lymphocytes, which are important in combating cancer cells. Clinical studies have shown that TRX518 can enhance response to cancer therapy and improve survival in patients with advanced melanoma. Leap Therapeutics' business model is based on the development and commercialization of novel therapeutics. The company collaborates closely with other biotech companies, as well as academic institutions and clinical centers, to accelerate the development of new therapies and bring them to market as quickly as possible. Overall, Leap Therapeutics is a promising biotechnology company specializing in the development of new cancer therapies. Through the targeted combination of drugs and the focus on specific target molecules, the aim is to develop highly effective therapies that offer advanced cancer patients better chances of survival and a higher quality of life. Leap Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Liabilities Details

Assessing Leap Therapeutics's Liabilities

Leap Therapeutics's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Leap Therapeutics's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Leap Therapeutics's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Leap Therapeutics's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Leap Therapeutics’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Leap Therapeutics Stock

What is the level of liabilities of Leap Therapeutics this year?

Leap Therapeutics has a debt balance of 12.68 M USD this year.

What were the liabilities of Leap Therapeutics compared to the previous year?

The liabilities of Leap Therapeutics have increased by 10.3% increased compared to the previous year.

What are the consequences of high debt for investors of Leap Therapeutics?

High liabilities can pose a risk for investors of Leap Therapeutics, as they can weaken the company's financial position and impair its ability to meet its obligations.

What consequences do low liabilities have for investors in Leap Therapeutics?

Low liabilities mean that Leap Therapeutics has a strong financial position and is able to meet its obligations without overburdening its finances.

How does an increase in liabilities of Leap Therapeutics affect the company?

An increase in liabilities of Leap Therapeutics can lead to the company having more obligations and potentially find it more difficult to meet its financial commitments.

How does a reduction in the liabilities of Leap Therapeutics affect the company?

A decrease in the liabilities of Leap Therapeutics can lead to the company having fewer obligations and a stronger financial position, which can make it easier for the company to fulfill its financial commitments.

What are some factors that influence the liabilities of Leap Therapeutics?

Some factors that can influence the liabilities of Leap Therapeutics include investments, acquisitions, operating costs, and sales development.

Why is the level of liabilities of Leap Therapeutics so important for investors?

The liabilities of Leap Therapeutics are important for investors as they serve as an indicator of the company's financial stability and provide investors with information on how the company meets its financial obligations.

What strategic measures can Leap Therapeutics take to modify the liabilities?

To change its liabilities, Leap Therapeutics can take measures such as cost savings, increasing revenue, selling assets, raising investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to choose the best strategic actions.

How much dividend does Leap Therapeutics pay?

Over the past 12 months, Leap Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Leap Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Leap Therapeutics?

The current dividend yield of Leap Therapeutics is .

When does Leap Therapeutics pay dividends?

Leap Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Leap Therapeutics?

Leap Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Leap Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Leap Therapeutics located?

Leap Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Leap Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Leap Therapeutics from 4/28/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 4/28/2024.

When did Leap Therapeutics pay the last dividend?

The last dividend was paid out on 4/28/2024.

What was the dividend of Leap Therapeutics in the year 2023?

In the year 2023, Leap Therapeutics distributed 0 USD as dividends.

In which currency does Leap Therapeutics pay out the dividend?

The dividends of Leap Therapeutics are distributed in USD.